Predictive value of ASCA and ANCA in inflammatory bowel diseases
| Autor: | D. A. Kuznetsova, S. V. Lapin, O. B. Shchukina, I. V. Gubonina, A. A. Kamanin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 31, Iss 1, Pp 37-46 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1607-4181 2541-8807 |
| DOI: | 10.24884/1607-4181-2024-31-1-37-46 |
| Popis: | Introduction. Serological diagnosis of inflammatory bowel diseases (IBD) is an additional tool not only for differential diagnosis, but also for individual prediction of the clinical course and long-term outcomes of Crohn’s disease (CD) and ulcerative colitis (UC).The objective was to assess the occurrence and capabilities of determining antibodies to Saccharomyces cerevisiae (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) in predicting the clinical outcomes of IBD.Methods and materials. The study included 71 patients with CD, 26 with UC, and 21 with and 21 with IBD unclassified (IBDU). The comparison group consisted of 35 patients with other gastrointestinal diseases (irritable bowel syndrome with diarrhea (IBS-D), celiac disease, autoimmune gastritis (AIG)); the control group consisted of 24 apparently healthy individuals. The level of antibodies to ASCA IgA and IgG was measured by the ELISA method (ORGENTEC Diagnostika GmbH, Germany), ANCA IgG was determined by the IIF method of the Granulocyte Mosaic test system (EUROIMMUN AG, Germany).Results. The occurrence of ASCA IgA and IgG in patients with CD was 25 % and 38 %, which is significantly higher compared to patients with UC (0 % and 3.8 %), IBDU (5 % and 5 %), AIG (0 % and 5.3 %) respectively (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|